MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ADMA Biologics Inc - Common Stock (NQ:ADMA)

13.20 -0.39 (-2.87%)
Streaming Delayed Price Updated: 11:29 AM EDT, Mar 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ADMA Biologics Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
How Is The Market Feeling About ADMA Biologics? ↗
 
Via Benzinga
News headline image
ADMA BIOLOGICS INC (NASDAQ:ADMA) – A Promising Affordable Growth Stock ↗
ADMA Biologics (NASDAQ:ADMA) shows strong growth, reasonable valuation, and solid financial health, making it an attractive candidate for investors seeking affordable growth stocks in the biotech... 
Via Chartmill
News headline image
ADMA BIOLOGICS INC (NASDAQ:ADMA) is not too expensive for the growth it is showing. ↗
Discover ADMA BIOLOGICS INC, an undervalued growth gem. NASDAQ:ADMA is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill
News headline image
Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings ↗
 
Via Benzinga
News headline image
Why IBD 50's No. 2 Stock, ADMA Biologics, Just Plummeted By Double Digits ↗
The company makes immunoglobulin products using donated plasma. 
Via Investor's Business Daily
Topics Earnings
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
ADMA Biologics Earnings Preview ↗
 
Via Benzinga
News headline image
What's Driving the Market Sentiment Around ADMA Biologics? ↗
 
Via Benzinga
News headline image
ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
3 Mid-Cap Medical Stocks Outperforming the Market
Several mid-cap medical stocks, such as ADMA, PEN, and TMDX, are outperforming in 2025, showing resilience despite broader market weakness. 
Via MarketBeat
Topics Economy
News headline image
Should you consider ADMA BIOLOGICS INC (NASDAQ:ADMA) for growth investing? ↗
A fundamental analysis of (NASDAQ:ADMA): Exploring growth characteristics of ADMA BIOLOGICS INC (NASDAQ:ADMA). 
Via Chartmill
News headline image
Would Mark Minervini consider ADMA BIOLOGICS INC (NASDAQ:ADMA) a top stock pick? ↗
A fundamental and technical analysis of (NASDAQ:ADMA): Exploring ADMA BIOLOGICS INC (NASDAQ:ADMA)'s high growth characteristics. 
Via Chartmill
News headline image
ADMA Biologics Inc (NASDAQ:ADMA): A Strong Minervini Trend Template Candidate ↗
ADMA Biologics Inc (NASDAQ:ADMA): A Strong Minervini Trend Template Candidate 
Via Chartmill
News headline image
ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025
Conference Call Scheduled for May 7, 2025, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
What's Going On With ADMA Stock Monday? ↗
ADM shares are trading higher Monday after the company announced the FDA's approval of its yield enhancement process. 
Via Benzinga
News headline image
Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:POAI),(NASDAQ:ADMA) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
IBD 50's Top Seed, ADMA, Just Rocketed On A New FDA Approval ↗
The company says a new process will improve its output by 20%, benefitting revenue and earnings later this year. 
Via Investor's Business Daily
News headline image
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
From FN Media Group LLC
Via GlobeNewswire
News headline image
ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
Why ADMA BIOLOGICS INC (NASDAQ:ADMA) qualifies as a high growth stock. ↗
A fundamental and technical analysis of (NASDAQ:ADMA): Is ADMA BIOLOGICS INC (NASDAQ:ADMA) suited for high growth investing? 
Via Chartmill
News headline image
Investors seeking growth at a reasonable cost should explore ADMA BIOLOGICS INC (NASDAQ:ADMA). ↗
Discover ADMA BIOLOGICS INC, an undervalued growth gem. NASDAQ:ADMA is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill
News headline image
ADMA Biologics Statement on Tariffs
Reiterates Strategic Advantage Through Fully U.S.-Based Manufacturing Operations, Commercialization and End-Market Sales, and Vertically Integrated U.S.-Based Supply Chain 
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
What's Driving the Market Sentiment Around ADMA Biologics? ↗
 
Via Benzinga
News headline image
ADMA BIOLOGICS INC (NASDAQ:ADMA) is showing good growth, while it is not too expensive. ↗
NASDAQ:ADMA is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. 
Via Chartmill
News headline image
Adma Biologics' Retail Traders Eye Higher Open After Blowout Q4, Strong Full-Year Outlook ↗
CEO Adam Grossman highlighted a 65% year-over-year jump in total revenue and a staggering 309% increase in adjusted EBITDA for 2024. 
Via Stocktwits
News headline image
ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 3, 2025 ↗
 
Via Benzinga
News headline image
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
From ADMA Biologics, Inc.
Via GlobeNewswire
News headline image
ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
Conference Call Scheduled for March 3, 2025, at 4:30 p.m. ET 
From ADMA Biologics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story